This RSS feed URL is deprecated, please update. New URLs can be found in the footers at

Eculizumab Found Safe and Effective for Myasthenia Gravis
LWW Journals
In a post-hoc analysis, eculizumab was found safe and effective for reducing symptoms in patients with generalized myasthenia gravis who have not responded to the standard treatments used in the autoimmune disease. Eculizumab, a drug that blocks the ...

Antibiotics That Aggravate Myasthenia Gravis
Pharmacy Times
Azevedo E, Ribeiro JA, Polonia J, Pontes C. Probable exacerbation of myasthenia gravis by ofloxacin. J Neurol. 1993;240(8):508. Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing ...
Myasthenia Gravis Market Report to Gain the Best Competitive Advantage; Profitable CollectionsatPRnews (press release)

all 3 news articles »


Alexion aims for best-ever Soliris launch with new myasthenia gravis indication
SAN FRANCISCO—Alexion's rollout of Soliris in generalized myasthenia gravis (MG) won't be just any launch for the rare-disease product. The company thinks it can make the kickoff its best ever. “We expect that the MG opportunity and launch will be at ...

Science Trends

First Report Of Humanizing An Antibody Fragment To Block Alleles Linked To Myasthenia Gravis
Science Trends
There are more than 80 types of autoimmune diseases among which our lab focused on myasthenia gravis (MG). MG is a T-cell-mediated autoimmune disorder caused by the presence of autoantibodies to acetylcholine receptor (AchR) – or muscle-specific ...

MG Patient Successfully Treated with Weekly Blood Purification Therapy, Case Report Says
Myasthenia Gravis News
Japanese researchers wrote about a myasthenia gravis (MG) patient who showed long-term improvement in disease symptoms after he was treated with blood purification therapy. The case report, “A Case of Anti-MuSK Antibody-positive Myasthenia Gravis ...

GT Biopharma Announces Completion of Dosing in Phase 1 Clinical ...
PR Newswire (press release)
GT Biopharma Inc. (OTCQB: GTBP) and (Euronext Paris: GTBP.PA) today announced that it has completed dosing in its Phase 1 clinical trial for GTP-004, its promising treatment for the symptoms of myasthenia gravis. The results provide evidence that GTP ...

and more »

Myasthenia Gravis News

Dosing Completed in Phase 1 Study of GTP-004 for Myasthenia Gravis Treatment Side Effects
Myasthenia Gravis News
Dosing has been completed in the Phase 1 clinical trial of GTP-004, a new candidate for the treatment of symptoms associated with myasthenia gravis (MG), including gastrointestinal side effects of pyridostigmine, the investigational therapy's developer ...

Myasthenia Gravis News

Long-term Use of Prograf May Increase Risk of Lymphoma in MG Patients, Case Report Suggests
Myasthenia Gravis News
Researchers have found that the long-term use of the immunosuppressive drug Prograf (tacrolimus) may contribute to the development of lymphoma in patients with myasthenia gravis (MG). This finding resulted from a case report published in Internal ...

Hartford Business

Soliris® (Eculizumab) Receives Marketing Authorization in Japan for ...
Business Wire (press release)
Alexion announced that the MHLW in Japan has approved Soliris as a treatment for patients with gMG who are anti-AChR anti-body positive.
Alexion's Soliris receives marketing authorization in Japan for the ...Seeking Alpha
Alexion drug greenlighted for use in JapanHartford Business
Alexion Pharma Announces Marketing Authorization For Soliris In JapanNasdaq

all 3 news articles »

Soliris Approved to Treat Myasthenia Gravis Patients Who Are AChR Antibody-positive in Japan
Myasthenia Gravis News
That decision, by that country's Ministry of Health, Labor and Welfare, makes Soliris the first and only complement inhibitor approved in Japan to treat gMG in patients who are anti-acetylcholine receptor (AChR) antibody-positive and whose symptoms are ...

Google News